

B7

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
10 May 2002 (10.05.2002)

PCT

(10) International Publication Number  
WO 02/36797 A2(51) International Patent Classification<sup>7</sup>: C12P 13/00

(21) International Application Number: PCT/EP01/11228

(22) International Filing Date:  
28 September 2001 (28.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

100 54 748.6	4 November 2000 (04.11.2000)	DE
60/248,210	15 November 2000 (15.11.2000)	US
101 12 107.5	14 March 2001 (14.03.2001)	DE
60/283,612	16 April 2001 (16.04.2001)	US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

(71) Applicant: DEGUSSA AG [DE/DE]; Bennigseplatz 1, 40474 Düsseldorf (DE).

(72) Inventors: RIEPING, Mechthild; Mönkebergstrasse 1, 33619 Bielefeld (DE). THIERBACH, Georg; Gunststrasse 21, 33613 Bielefeld (DE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/36797 A2

(54) Title: PROCESS FOR THE FERMENTATIVE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEAE FAMILY

(57) Abstract: The invention relates to a process for the fermentative preparation of L-amino acids, in particular L-threonine, in which the following steps are carried out: a) fermentation of the microorganisms of the Enterobacteriaceae family which produce the desired L-amino acid and in which at least the *poxB* gene or nucleotide sequences which code for it are attenuated, in particular eliminated, b) concentration of the L-amino acid in the medium or in the cells of the bacteria and c) isolation of the L-amino acid.

**Process for the fermentative preparation of L-amino acids  
using strains of the Enterobacteriaceae family**

This invention relates to a process for the fermentative preparation of L-amino acids, in particular L-threonine,  
5 L-lysine and L-valine, using strains of the Enterobacteriaceae family in which the poxB gene is attenuated.

**Prior Art**

L-Amino acids, in particular L-threonine, L-lysine and  
10 L-valine are used in human medicine and in the pharmaceuticals industry, in the foodstuffs industry and very particularly in animal nutrition.

It is known to prepare L-amino acids by fermentation of strains of Enterobacteriaceae, in particular Escherichia  
15 coli (E. coli) and Serratia marcescens. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as e.g. stirring and supply of oxygen, or the composition of the  
20 nutrient media, such as e.g. the sugar concentration during the fermentation, or the working up to the product form, by e.g. ion exchange chromatography, or the intrinsic output properties of the microorganism itself.

Methods of mutagenesis, selection and mutant selection are  
25 used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites, such as e.g. the threonine analogue  $\alpha$ -amino- $\beta$ -hydroxyvaleric acid (AHV), or are auxotrophic for metabolites of regulatory importance and produce L-amino  
30 acid, such as e.g. L-threonine, are obtained in this manner.

Methods of the recombinant DNA technique have also been employed for some years for improving the strain of

strains of the Enterobacteriaceae family which produce L-amino acids, by amplifying individual amino acid biosynthesis genes and investigating the effect on the production.

## 5 Object of the Invention

The inventors had the object of providing new measures for improved fermentative preparation of L-amino acids, in particular L-threonine, L-lysine and L-valine.

## Description of the Invention

- 10 The invention provides a process for the fermentative preparation of L-amino acids, in particular L-threonine, using microorganisms of the Enterobacteriaceae family which, in particular, already produce L-threonine and in which the nucleotide sequence which codes for the enzyme  
15 pyruvate oxidase (EC 1.2.2.2) (poxB gene) is attenuated.

The term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak  
20 promoter or a gene or allele which codes for a corresponding enzyme with a low activity or inactivates the corresponding enzyme (protein) or gene, and optionally combining these measures.

The process comprises carrying out the following steps:

- 25 a) fermentation of microorganisms of the Enterobacteriaceae family in which at least the poxB gene is attenuated,  
b) concentration of the corresponding L-amino acid in the medium or in the cells of the microorganisms of  
30 the Enterobacteriaceae family, and  
c) isolation of the desired L-amino acid.

The microorganisms which the present invention provides can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, optionally starch, optionally cellulose or from glycerol and ethanol. They are  
5 representatives of the Enterobacteriaceae family chosen from the genera *Escherichia*, *Erwinia*, *Providencia* and *Serratia*. The genera *Escherichia* and *Serratia* are preferred. Of the genus *Escherichia* the species *Escherichia coli* and of the genus *Serratia* the species *Serratia*  
10 *marcescens* are to be mentioned in particular.

Suitable strains, which produce L-threonine in particular, of the genus *Escherichia*, in particular of the species *Escherichia coli*, are, for example

15 *Escherichia coli* TF427  
*Escherichia coli* H4578  
*Escherichia coli* KY10935  
*Escherichia coli* VNIIGenetika MG442  
*Escherichia coli* VNIIGenetika M1  
20 *Escherichia coli* VNIIGenetika 472T23  
*Escherichia coli* BKIIM B-3996  
*Escherichia coli* kat 13  
*Escherichia coli* KCCM-10132

Suitable L-threonine-producing strains of the genus *Serratia*, in particular of the species *Serratia marcescens*,  
25 are, for example

*Serratia marcescens* HNr21  
*Serratia marcescens* Tlr156  
*Serratia marcescens* T2000.

Strains from the Enterobacteriaceae family which produce  
30 L-threonine preferably have, inter alia, one or more genetic or phenotypic features chosen from the group consisting of: resistance to  $\alpha$ -amino- $\beta$ -hydroxyvaleric acid, resistance to thialysine, resistance to ethionine,

resistance to  $\alpha$ -methylserine, resistance to diaminosuccinic acid, resistance to  $\alpha$ -aminobutyric acid, resistance to borrelidin, resistance to rifampicin, resistance to valine analogues, such as, for example, valine hydroxamate,

5 resistance to purine analogues, such as, for example, 6-dimethylaminopurine, a need for L-methionine, optionally a partial and compensatable need for L-isoleucine, a need for meso-diaminopimelic acid, auxotrophy in respect of threonine-containing dipeptides, resistance to L-threonine,

10 resistance to L-homoserine, resistance to L-lysine, resistance to L-methionine, resistance to L-glutamic acid, resistance to L-aspartate, resistance to L-leucine, resistance to L-phenylalanine, resistance to L-serine, resistance to L-cysteine, resistance to L-valine,

15 sensitivity to fluoropyruvate, defective threonine dehydrogenase, optionally a capacity for sucrose utilization, enhancement of the threonine operon, enhancement of homoserine dehydrogenase I-aspartate kinase I, preferably of the feedback-resistant form, enhancement

20 of homoserine kinase, enhancement of threonine synthase, enhancement of aspartate kinase, optionally of the feedback-resistant form, enhancement of aspartate semialdehyde dehydrogenase, enhancement of phosphoenol pyruvate carboxylase, optionally of the feedback-resistant

25 form, enhancement of phosphoenol pyruvate synthase, enhancement of transhydrogenase, enhancement of the RhtB gene product, enhancement of the RhtC gene product, enhancement of the YfiK gene product, enhancement of a pyruvate carboxylase, and attenuation of acetic acid

30 formation.

It has been found that microorganisms of the Enterobacteriaceae family produce L-amino acids, in particular L-threonine, in an improved manner after attenuation, in particular elimination, of the poxB gene,

35 which codes for pyruvate oxidase (EC number 1.2.2.2).

It has furthermore been found that microorganisms of the Enterobacteriaceae family form lower concentrations of the undesirable by-product acetic acid after attenuation, in particular elimination, of the *poxB* gene, which codes for  
5 pyruvate oxidase (EC number 1.2.2.2).

The nucleotide sequence of the *poxB* gene of *Escherichia coli* has been published by Grabau and Cronan (Nucleic Acids Research. 14 (13), 5449-5460 (1986)) and can also be found from the genome sequence of *Escherichia coli* published by  
10 Blattner et al. (Science 277, 1453 - 1462 (1997)), under Accession Number AE000188. The nucleotide sequence of the *poxB* gene of *Escherichia coli* is shown in SEQ ID No. 1 and the amino acid sequence of the associated gene product is shown in SEQ ID No. 2.

15 The *poxB* genes described in the text references mentioned can be used according to the invention. Alleles of the *poxB* gene which result from the degeneracy of the genetic code or due to "sense mutations" of neutral function can furthermore be used.

20 To achieve an attenuation, for example, expression of the *poxB* gene or the catalytic properties of the enzyme protein can be reduced or eliminated. The two measures can optionally be combined.

The reduction in gene expression can take place by suitable  
25 culturing, by genetic modification (mutation) of the signal structures of gene expression or also by the antisense-RNA technique. Signal structures of gene expression are, for example, repressor genes, activator genes, operators, promoters, attenuators, ribosome binding sites, the start  
30 codon and terminators. The expert can find information in this respect, inter alia, for example, in Jensen and Hammer (Biotechnology and Bioengineering 58: 191-195 (1998)), in Carrier and Keasling (Biotechnology Progress 15, 58-64 (1999), Franch and Gerdes (Current Opinion in Microbiology

3, 159-164 (2000)) and in known textbooks of genetics and molecular biology, such as, for example, the textbook of Knippers ("Molekulare Genetik [Molecular Genetics]", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995) or  
5 that of Winnacker ("Gene und Klone [Genes and Clones]", VCH Verlagsgesellschaft, Weinheim, Germany, 1990).

Mutations which lead to a change or reduction in the catalytic properties of enzyme proteins are known from the prior art. Examples which may be mentioned are the works of  
10 Qiu and Goodman (Journal of Biological Chemistry 272: 8611-8617 (1997)), Yano et al. (Proceedings of the National Academy of Sciences, USA 95, 5511-5515 (1998), Wentz and Schachmann (Journal of Biological Chemistry 266, 20833-20839 (1991). Summarizing descriptions can be found in  
15 known textbooks of genetics and molecular biology, such as e.g. that by Hagemann ("Allgemeine Genetik ", Gustav Fischer Verlag, Stuttgart, 1986).

Possible mutations are transitions, transversions, insertions and deletions. Depending on the effect of the  
20 amino acid exchange on the enzyme activity, "missense mutations" or "nonsense mutations" are referred to. Insertions or deletions of at least one base pair in a gene lead to "frame shift mutations", which lead to incorrect amino acids being incorporated or translation being  
25 interrupted prematurely. Deletions of several codons typically lead to a complete loss of the enzyme activity. Instructions on generation of such mutations are prior art and can be found in known textbooks of genetics and molecular biology, such as e.g. the textbook by Knippers  
30 ("Molekulare Genetik [Molecular Genetics]", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995), that by Winnacker ("Gene und Klone ", VCH Verlagsgesellschaft, Weinheim, Germany, 1990) or that by Hagemann ("Allgemeine Genetik ", Gustav Fischer Verlag, Stuttgart, 1986).

An example of a plasmid with the aid of which the *poxB* gene of *Escherichia coli* can be attenuated, in particular eliminated, by position-specific mutagenesis is the plasmid pMAK705 $\Delta$ *poxB* (figure 1). In addition to residues of polylinker sequences, it contains only a part of the 5' and a part of the 3' region of the *poxB* gene. A 340 bp long section of the coding region is missing (deletion). The sequence of this DNA which can be employed for mutagenesis of the *poxB* gene is shown in SEQ ID No. 3.

- 10 The deletion mutation of the *poxB* gene can be incorporated into suitable strains by gene or allele replacement.

A conventional method is the method, described by Hamilton et al. (Journal of Bacteriology 174, 4617 - 4622 (1989)), of gene replacement with the aid of a conditionally replicating pSC101 derivative pMAK705. Other methods described in the prior art, such as, for example, those of Martinez-Morales et al. (Journal of Bacteriology 1999, 7143-7148 (1999)) or those of Boyd et al. (Journal of Bacteriology 182, 842-847 (2000)), can likewise be used.

- 15  
20 After replacement has taken place, the strain in question contains the form of the  $\Delta$ *poxB* allele shown in SEQ ID No. 4, which is also provided by the invention.

It is also possible to transfer mutations in the *poxB* gene or mutations which affect expression of the *poxB* gene into various strains by conjugation or transduction.

- 25  
It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, with strains of the Enterobacteriaceae family to enhance one or more enzymes of the known threonine biosynthesis pathway or enzymes of anaplerotic metabolism or enzymes for the production of reduced nicotinamide adenine dinucleotide phosphate, in addition to the attenuation of the *poxB* gene.
- 30



The term "enhancement" in this connection describes the increase in the intracellular activity of one or more enzymes or proteins in a microorganism which are coded by the corresponding DNA, for example by increasing the number  
5 of copies of the gene or genes, using a potent promoter or a gene which codes for a corresponding enzyme or protein with a high activity, and optionally combining these measures.

Thus, for example, one or more genes chosen from the group  
10 consisting of

- the thrABC operon which codes for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase (US-A-4,278,765),
- the pyc gene which codes for pyruvate carboxylase  
15 (DE-A-19 831 609),
- the pps gene which codes for phosphoenol pyruvate synthase (Molecular and General Genetics 231:332 1992)),
- the ppc gene which codes for phosphoenol pyruvate carboxylase (Gene 31:279-283 (1984)),
- 20 • the pntA and pntB genes which code for transhydrogenase (European Journal of Biochemistry 158:647-653 (1986)),
- the rhtB gene which imparts homoserine resistance (EP-A-0 994 190),
- the mqo gene which codes for malate:quinone  
25 oxidoreductase (DE 100 348 33.5),
- the rhtC gene which imparts threonine resistance (EP-A-1 013 765), and
- the thrE gene of Corynebacterium glutamicum which codes for threonine export (DE 100 264 94.8) and

- the *gdhA* gene which codes for glutamate dehydrogenase (Nucleic Acids Research 11: 5257-5266 (1983); Gene 23: 199-209 (1983))

can be enhanced, in particular over-expressed, at the same  
5 time.

It may furthermore be advantageous for the production of L-amino acids, in particular threonine, in addition to the attenuation of the *poxB* gene, for one or more genes chosen from the group consisting of

- 10 • the *tdh* gene which codes for threonine dehydrogenase (Ravnikar and Somerville, Journal of Bacteriology 169, 4716-4721 (1987)),
- the *mdh* gene which codes for malate dehydrogenase (E.C. 1.1.1.37) (Vogel et al., Archives in Microbiology 149,  
15 36-42 (1987)),
- the gene product of the open reading frame (orf) *yjfa* (Accession Number AAC77180 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA),
- the gene product of the open reading frame (orf) *ytff*  
20 (Accession Number AAC77179 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA) and
- the *pckA* gene which codes for the enzyme phosphoenolpyruvate carboxykinase (Medina et al. (Journal of Bacteriology 172, 7151-7156 (1990))
- 25 to be attenuated, in particular eliminated or reduced in expression.

In addition to attenuation of the *poxB* gene it may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, to eliminate undesirable  
30 side reactions (Nakayama: "Breeding of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products,

Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).

The microorganisms produced according to the invention can be cultured in the batch process (batch culture), the fed  
5 batch (feed process) or the repeated fed batch process (feed process). A summary of known culture methods is described in the textbook by Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik [Bioprocess  
Technology 1. Introduction to Bioprocess Technology (Gustav  
10 Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions  
15 of culture media for various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981).

Sugars and carbohydrates, such as e.g. glucose, sucrose,  
20 lactose, fructose, maltose, molasses, starch and optionally cellulose, oils and fats, such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as e.g. palmitic acid, stearic acid and linoleic acid,  
alcohols, such as e.g. glycerol and ethanol, and organic  
25 acids, such as e.g. acetic acid, can be used as the source of carbon. These substances can be used individually or as a mixture.

Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep  
30 liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen. The sources of nitrogen can be used individually or as a mixture.

Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the source of phosphorus. The culture medium must furthermore comprise salts of  
5 metals, such as e.g. magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth substances, such as amino acids and vitamins, can be employed in addition to the abovementioned substances. Suitable precursors can moreover be added to the culture  
10 medium. The starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.

Basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds,  
15 such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH. Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam. Suitable substances having a selective action, e.g. antibiotics, can be added  
20 to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as e.g. air, are introduced into the culture. The temperature of the culture is usually 25°C to 45°C, and preferably 30°C to 40°C. Culturing is continued  
25 until a maximum of L-amino acids or L-threonine has formed. This target is usually reached within 10 hours to 160 hours.

The analysis of L-amino acids can be carried out by anion exchange chromatography with subsequent ninhydrin  
30 derivatization, as described by Spackman et al. (Analytical Chemistry, 30, (1958), 1190), or it can take place by reversed phase HPLC as described by Lindroth et al. (Analytical Chemistry (1979) 51: 1167-1174).

A pure culture of the Escherichia coli K-12 strain  
35 DH5 $\alpha$ /pMAK705 was deposited as DSM 13720 on 8th September

2000 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty.

- 5 A pure culture of the Escherichia coli K-12 strain MG442ApoxB was deposited as DSM 13762 on 2nd October 2000 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance  
10 with the Budapest Treaty.

The process according to the invention is used for the fermentative preparation of L-amino acids, such as e.g. L-thrèonine, L-isoleucine, L-valine, L-methionine, L-homoserine and L-lysine, in particular L-threonine.

- 15 The present invention is explained in more detail in the following with the aid of embodiment examples.

The isolation of plasmid DNA from Escherichia coli and all techniques of restriction, Klenow and alkaline phosphatase treatment are carried out by the method of Sambrook et al.

- 20 (Molecular cloning - A laboratory manual (1989) Cold Spring Harbour Laboratory Press). Unless described otherwise, the transformation of Escherichia coli is carried out by the method of Chung et al. (Proceedings of the National Academy of Sciences of the United States of America USA (1989) 86:  
25 2172-2175).

The incubation temperature for the preparation of strains and transformants is 37°C. Temperatures of 30°C and 44°C are used in the gene replacement method of Hamilton et. al.

Example 1

Construction of the deletion mutation of the poxB gene

Parts of the 5' and 3' region of the poxB gene are amplified from Escherichia coli K12 using the polymerase chain reaction (PCR) and synthetic oligonucleotides. Starting from the nucleotide sequence of the poxB gene in E. coli K12 MG1655 (SEQ ID No. 1), the following PCR primers are synthesized (MWG Biotech, Ebersberg, Germany):

poxB'5'-1: 5' - CTGAACGGTCTTAGTGACAG - 3'

10 poxB'5'-2: 5' - AGGCCTGGAATAACGCAGCAGTTG - 3'

poxB'3'-1: 5' - CTGCGTGCATTGCTTCCATTG - 3'

poxB'3'-2: 5' - GCCAGTTCGATCACTTCATCAC - 3'

The chromosomal E. coli K12 MG1655 DNA employed for the PCR is isolated according to the manufacturers instructions. 15 with "Qiagen Genomic-tips 100/G" (QIAGEN, Hilden, Germany). A DNA fragment approx. 500 base pairs (bp) in size from the 5' region of the poxB gene (called poxB1) and a DNA fragment approx. 750 bp in size from the 3' region of the poxB gene (called poxB2) can be amplified with the specific 20 primers under standard PCR conditions (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) with Taq-DNA polymerase (Gibco-BRL, Eggenstein, Germany). The PCR products are each ligated with the vector pCR2.1TOPO (TOPO TA Cloning Kit, 25 Invitrogen, Groningen, The Netherlands) in accordance with the manufacturers instructions and transformed into the E. coli strain TOP10F'.

Selection of plasmid-carrying cells takes place on LB agar, to which 50 µg/ml ampicillin are added. After isolation of 30 the plasmid DNA, the vector pCR2.1TOPOpoxB1 is cleaved with the restriction enzymes Ecl136II and XbaI and, after

- separation in 0.8% agarose gel, the poxB1 fragment is isolated with the aid of the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany). After isolation of the plasmid DNA the vector pCR2.1TOPOpoxB2 is cleaved with the enzymes
- 5 EcoRV and XbaI and ligated with the poxB1 fragment isolated. The E. coli strain DH5 $\alpha$  is transformed with the ligation batch and plasmid-carrying cells are selected on LB agar, to which 50  $\mu$ g/ml ampicillin is added. After isolation of the plasmid DNA those plasmids in which the
- 10 mutagenic DNA sequence shown in SEQ ID No. 3 is cloned are detected by control cleavage with the enzymes HindIII and XbaI. One of the plasmids is called pCR2.1TOPO $\Delta$ poxB.

#### Example 2

Construction of the replacement vector pMAK705 $\Delta$ poxB

- 15 The poxB allele described in Example 1 is isolated from the vector pCR2.1TOPO $\Delta$ poxB after restriction with the enzymes HindIII and XbaI and separation in 0.8% agarose gel, and ligated with the plasmid pMAK705 (Hamilton et al. (1989) Journal of Bacteriology 174, 4617 - 4622), which has been
- 20 digested with the enzymes HindIII and XbaI. The ligation batch is transformed in DH5 $\alpha$  and plasmid-carrying cells are selected on LB agar, to which 20  $\mu$ g/ml chloramphenicol is added. Successful cloning is demonstrated after isolation of the plasmid DNA and cleavage with the enzymes HindIII
- 25 and XbaI. The replacement vector formed, pMAK705 $\Delta$ poxB (= pMAK705 $\Delta$ poxB), is shown in figure 1.

#### Example 3

Position-specific mutagenesis of the poxB gene in the E. coli strain MG442

- 30 The L-threonine-producing E. coli strain MG442 is described in the patent specification US-A- 4,278,765 and deposited as CMIM B-1628 at the Russian National Collection for Industrial Microorganisms (VKPM, Moscow, Russia).

For replacement of the chromosomal *poxB* gene with the plasmid-coded deletion construct, MG442 is transformed with the plasmid pMAK705 $\Delta$ *poxB*. The gene replacement is carried out by the selection method described by Hamilton et al.

- 5 (1989) Journal of Bacteriology 174, 4617 - 4622) and is verified by standard PCR methods (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) with the following oligonucleotide primers:

*poxB*'5'-1: 5' - CTGAACGGTCTTAGTGACAG - 3'

- 10 *poxB*'3'-2: 5' - GCCAGTTCGATCACTTCATCAC -3'

The strain obtained is called MG442 $\Delta$ *poxB*.

#### Example 4

Preparation of L-threonine with the strain MG442 $\Delta$ *poxB*

- MG442 $\Delta$ *poxB* is multiplied on minimal medium with the following composition: 3.5 g/l Na<sub>2</sub>HPO<sub>4</sub>\*2H<sub>2</sub>O, 1.5 g/l KH<sub>2</sub>PO<sub>4</sub>, 1 g/l NH<sub>4</sub>Cl, 0.1 g/l MgSO<sub>4</sub>\*7H<sub>2</sub>O, 2 g/l glucose, 20 g/l agar. The formation of L-threonine is checked in batch cultures of 10 ml contained in 100 ml conical flasks. For this, 10 ml of preculture medium of the following composition:
- 20 2 g/l yeast extract, 10 g/l (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 1 g/l KH<sub>2</sub>PO<sub>4</sub>, 0.5 g/l MgSO<sub>4</sub>\*7H<sub>2</sub>O, 15 g/l CaCO<sub>3</sub>, 20 g/l glucose are inoculated and the batch is incubated for 16 hours at 37°C and 180 rpm on an ESR incubator from Kühner AG (Birsfelden, Switzerland). 250  $\mu$ l of this preculture are transinoculated into 10 ml of
- 25 production medium (25 g/l (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2 g/l KH<sub>2</sub>PO<sub>4</sub>, 1 g/l MgSO<sub>4</sub>\*7H<sub>2</sub>O, 0.03 g/l FeSO<sub>4</sub>\*7H<sub>2</sub>O, 0.018 g/l MnSO<sub>4</sub>\*1H<sub>2</sub>O, 30 g/l CaCO<sub>3</sub>, 20 g/l glucose) and the batch is incubated for 48 hours at 37°C. After the incubation the optical density (OD) of the culture suspension is determined with an LP2W
- 30 photometer from Dr. Lange (Berlin, Germany) at a measurement wavelength of 660 nm.



The concentration of L-threonine formed is then determined in the sterile-filtered culture supernatant with an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column reaction  
5 with ninhydrin detection.

The result of the experiment is shown in Table 1.

Table 1

Strain	OD (660 nm)	L-Threonine g/l
MG442	6.0	1.5
MG442 $\Delta$ poxB	4.9	2.6

#### Example 5

- 10 Preparation of L-threonine with the strain  
MG442 $\Delta$ poxB/pMW218gdhA

##### 5.1 Amplification and cloning of the *gdhA* gene

- The glutamate dehydrogenase gene from *Escherichia coli* K12 is amplified using the polymerase chain reaction (PCR) and  
15 synthetic oligonucleotides. Starting from the nucleotide sequence for the *gdhA* gene in *E. coli* K12 MG1655 (gene library: Accession No. AE000270 and No. AE000271), PCR primers are synthesized (MWG Biotech, Ebersberg, Germany):

Gdh1: 5' - TGAACACTTCTGGCGGTACG - 3'

- 20 Gdh2: 5' - CCTCGGCGAAGCTAATATGG - 3'

The chromosomal *E. coli* K12 MG1655 DNA employed for the PCR is isolated according to the manufacturers instructions with "QIAGEN Genomic-tips 100/G" (QIAGEN, Hilden, Germany). A DNA fragment approx. 2150 bp in size, which comprises the

- gdhA coding region and approx. 350 bp 5'-flanking and approx. 450 bp 3'-flanking sequences, can be amplified with the specific primers under standard PCR conditions (Innis et al.: PCR protocols. A guide to methods and applications, 5 1990, Academic Press) with Pfu-DNA polymerase (Promega Corporation, Madison, USA). The PCR product is cloned in the plasmid pCR2.1TOPO and transformed in the E. coli strain TOP10 (Invitrogen, Leek, The Netherlands, Product Description TOPO TA Cloning Kit, Cat. No. K4500-01).
- 10 Successful cloning is demonstrated by cleavage of the plasmid pCR2.1TOPOgdhA with the restriction enzymes EcoRI and EcoRV. For this, the plasmid DNA is isolated by means of the "QIAprep Spin Plasmid Kit" (QIAGEN, Hilden, Germany) and, after cleavage, separated in a 0.8% agarose gel.
- 15 5.2 Cloning of the gdhA gene in the plasmid vector pMW218

The plasmid pCR2.1TOPOgdhA is cleaved with the enzyme EcoRI, the cleavage batch is separated on 0.8% agarose gel and the gdhA fragment 2.1 kbp in size is isolated with the aid of the "QIAquick Gel Extraction Kit" (QIAGEN, Hilden, 20 Germany). The plasmid pMW218 (Nippon Gene, Toyama, Japan) is cleaved with the enzyme EcoRI and ligated with the gdhA fragment. The E. coli strain DH5 $\alpha$  is transformed with the ligation batch and pMW218-carrying cells are selected by plating out on LB agar (Lennox, Virology 1955, 1: 190), to 25 which 20 $\mu$ g/ml kanamycin are added.

Successful cloning of the gdhA gene can be demonstrated after plasmid DNA isolation and control cleavage with EcoRI and EcoRV. The plasmid is called pMW218gdhA (figure 2).

### 5.3 Preparation of the strain MG442 $\Delta$ poxB/pMW218gdhA

- 30 The strain MG442 $\Delta$ poxB obtained in Example 3 and the strain MG442 are transformed with the plasmid pMW218gdhA and transformants are selected on LB agar, which is supplemented with 20  $\mu$ g/ml kanamycin. The strains

MG442 $\Delta$ poxB/pMW218gdhA and MG442/pMW218gdhA are formed in this manner.

#### 5.4 Preparation of L-threonine

The preparation of L-threonine by the strains  
5 MG442 $\Delta$ poxB/pMW218gdhA and MG442/pMW218gdhA is tested as described in Example 4. The minimal medium and the preculture medium are additionally supplemented with 20  $\mu$ g/ml kanamycin for these two strains.

The result of the experiment is summarized in Table 2.

10

Table 2

Strain	OD (660 nm)	L-Threonine g/l
MG442	6.0	1.5
MG442 $\Delta$ poxB	4.9	2.6
MG442/pMW218gdhA	5.6	2.6
MG442 $\Delta$ poxB/pMW218gdhA	5.5	2.9

#### Example 6

Preparation of L-threonine with the strain  
MG442 $\Delta$ poxB/pMW219rhtC

#### 15 6.1 Amplification of the rhtC gene

The rhtC gene from Escherichia coli K12 is amplified using the polymerase chain reaction (PCR) and synthetic oligonucleotides. Starting from the nucleotide sequence for the rhtC gene in E. coli K12 MG1655 (gene library:  
20 Accession No. AE000458, Zakataeva et al. (FEBS Letters 452,

228-232 (1999)), PCR primers are synthesized (MWG Biotech, Ebersberg, Germany):

RhtC1: 5' - CTGTTAGCATCGGCGAGGCA - 3'

RhtC2: 5' - GCATGTTGATGGCGATGACG - 3'

- 5 The chromosomal E. coli K12 MG1655 DNA employed for the PCR is isolated according to the manufacturers instructions with "QIAGEN Genomic-tips 100/G" (QIAGEN, Hilden, Germany). A DNA fragment approx. 800 bp in size can be amplified with the specific primers under standard PCR conditions (Innis et al.: PCR protocols. A guide to methods and applications, 1990, Academic Press) with Pfu-DNA polymerase (Promega Corporation, Madison, USA).

#### 6.2 Cloning of the rhtC gene in the plasmid vector pMW219

- The plasmid pMW219 (Nippon Gene, Toyama, Japan) is cleaved  
15 with the enzyme SamI and ligated with the rhtC-PCR fragment. The E. coli strain DH5 $\alpha$  is transformed with the ligation batch and pMW219-carrying cells are selected on LB agar, which is supplemented with 20  $\mu$ g/ml kanamycin. Successful cloning can be demonstrated after plasmid DNA  
20 isolation and control cleavage with KpnI, HindIII and NcoI. The plasmid pMW219rhtC is shown in figure 3.

#### 6.3 Preparation of the strain MG442 $\Delta$ poxB/pMW219rhtC

- The strain MG442 $\Delta$ poxB obtained in Example 3 and the strain MG442 are transformed with the plasmid pMW219rhtC and  
25 transformants are selected on LB agar, which is supplemented with 20  $\mu$ g/ml kanamycin. The strains MG442 $\Delta$ poxB/pMW219rhtC and MG442/pMW219rhtC are formed in this way.

#### 6.4 Preparation of L-threonine

- 30 The preparation of L-threonine by the strains MG442 $\Delta$ poxB/pMW219rhtC and MG442/pMW219rhtC is tested as

described in Example 4. The minimal medium and the preculture medium are additionally supplemented with 20 µg/ml kanamycin for these two strains.

The result of the experiment is summarized in Table 3.

5

Table 3

Strain	OD (660 nm)	L-Threonine g/l
MG442	6.0	1.5
MG442ΔpoxB	4.9	2.6
MG442/pMW219rhtC	5.2	2.9
MG442ΔpoxB/pMW219rhtC	5.4	3.9

#### Example 7

Position-specific mutagenesis of the poxB gene in the E. coli strain TOC21R

- 10 The L-lysine-producing E. coli strain pDA1/TOC21R is described in the patent application F-A-2511032 and deposited at the Collection Nationale de Culture de Microorganisme (CNCM = National Microorganism Culture Collection, Pasteur Institute, Paris, France) under number
- 15 I-167. The strain and the plasmid-free host are also described by Dauce-Le Reverend et al. (European Journal of Applied Microbiology and Biotechnology 15:227-231 (1982)) under the name TOC21/pDA1.

- After culture in antibiotic-free LB medium for
- 20 approximately six generations, a derivative of strain pDA1/TOC21R which no longer contains the plasmid pDA1 is

isolated. The strain formed is tetracycline-sensitive and is called TOC21R.

For replacement of the chromosomal poxB gene with the plasmid-coded deletion construct, TOC21R is transformed with the plasmid pMAK705 $\Delta$ poxB (Example 2). The gene replacement is carried out by the selection method described by Hamilton et al. (1989) Journal of Bacteriology 174, 4617 - 4622) and is verified by standard PCR methods (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) with the following oligonucleotide primers:

poxB'5'-1: 5' - CTGAACGGTCTTAGTGACAG - 3'

poxB'3'-2: 5' - GCCAGTTCGATCACTTCATCAC -3'

The strain obtained is called TOC21R $\Delta$ poxB.

#### 15 Example 8

Preparation of L-lysine with the strain TOC21R $\Delta$ poxB

The formation of L-lysine by the strains TOC21R $\Delta$ poxB and TOC21R is checked in batch cultures of 10 ml contained in 100 ml conical flasks. For this, 10 ml of preculture medium of the following composition: 2 g/l yeast extract, 10 g/l (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 1 g/l KH<sub>2</sub>PO<sub>4</sub>, 0.5 g/l MgSO<sub>4</sub>\*7H<sub>2</sub>O, 15 g/l CaCO<sub>3</sub>, 20 g/l glucose are inoculated and the batch is incubated for 16 hours at 37°C and 180 rpm on an ESR incubator from Kühner AG (Birsfelden, Switzerland). 250  $\mu$ l of this preculture are transinoculated into 10 ml of production medium (25 g/l (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2 g/l KH<sub>2</sub>PO<sub>4</sub>, 1 g/l MgSO<sub>4</sub>\*7H<sub>2</sub>O, 0.03 g/l FeSO<sub>4</sub>\*7H<sub>2</sub>O, 0.018 g/l MnSO<sub>4</sub>\*1H<sub>2</sub>O, 30 g/l CaCO<sub>3</sub>, 20 g/l glucose, 25 mg/l L-isoleucine and 5 mg/l thiamine) and the batch is incubated for 72 hours at 37°C. After the incubation the optical density (OD) of the culture suspension is determined with an LP2W photometer from Dr.

Lange (Berlin, Germany) at a measurement wavelength of 660 nm.

The concentration of L-lysine formed is then determined in the sterile-filtered culture supernatant with an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column reaction with ninhydrin detection.

The result of the experiment is shown in table 4.

Table 4

Strain	OD (660 nm)	L-Lysine g/l
TOC21R	1.0	1.17
TOC21RApoxB	1.0	1.29

10

#### Example 9

Position-specific mutagenesis of the poxB gene in the E. coli strain B-1288

The L-valine-producing E. coli strain AJ 11502 is described in the patent specification US-A-4391907 and deposited at the National Center for Agricultural Utilization Research (Peoria, Illinois, USA) as NRRL B-12288.

After culture in antibiotic-free LB medium for approximately six generations, a plasmid-free derivative of strain AJ 11502 is isolated. The strain formed is ampicillin-sensitive and is called AJ11502kur.

For replacement of the chromosomal poxB gene with the plasmid-coded deletion construct, AJ11502kur is transformed with the plasmid pMAK705ΔpoxB (see Example 2). The gene replacement is carried out by the selection method

described by Hamilton et al. (1989) Journal of Bacteriology 174, 4617 - 4622) and is verified by standard PCR methods (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) with the following  
5 oligonucleotide primers:

poxB'5'-1: 5' - CTGAACGGTCTTAGTGACAG - 3'

poxB'3'-2: 5' - GCCAGTTCGATCACTTCATCAC -3'

The strain obtained is called AJ11502kurApoxB. The plasmid described in the patent specification US-A-4391907, which  
10 carries the genetic information in respect of valine production, is isolated from strain NRRL B-12288. The strain AJ11502kurApoxB is transformed with this plasmid. One of the transformants obtained is called B-12288ApoxB.

#### Example 10

#### 15 Preparation of L-valine with the strain B-12288ApoxB

The formation of L-valine by the strains B-12288ApoxB and NRRL B-12288 is checked in batch cultures of 10 ml contained in 100 ml conical flasks. For this, 10 ml of preculture medium of the following composition: 2 g/l yeast  
20 extract, 10 g/l  $(\text{NH}_4)_2\text{SO}_4$ , 1 g/l  $\text{KH}_2\text{PO}_4$ , 0.5 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 15 g/l  $\text{CaCO}_3$ , 20 g/l glucose and 50 mg/l ampicillin are inoculated and the batch is incubated for 16 hours at 37°C and 180 rpm on an ESR incubator from Kühner AG (Birsfelden, Switzerland). 250 µl of this preculture are transinoculated  
25 into 10 ml of production medium (25 g/l  $(\text{NH}_4)_2\text{SO}_4$ , 2 g/l  $\text{KH}_2\text{PO}_4$ , 1 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 0.03 g/l  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ , 0.018 g/l  $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ , 30 g/l  $\text{CaCO}_3$ , 20 g/l glucose, 5 mg/l thiamine and 50 mg/l ampicillin) and the batch is incubated for 72 hours at 37°C. After the incubation the optical density  
30 (OD) of the culture suspension is determined with an LP2W photometer from Dr. Lange (Berlin, Germany) at a measurement wavelength of 660 nm.



The concentration of L-valine formed is then determined in the sterile-filtered culture supernatant with an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column reaction with  
5 ninhydrin detection.

The result of the experiment is shown in table 5.

Table 5

Strain	OD (660 nm)	L-Valine g/l
NRRL B-12288	5.7	0.95
B-12288 $\Delta$ poxB	5.6	1.05

#### Brief Description of the Figures

- 10 • Figure 1: pMAK705 $\Delta$ poxB ( = pMAK705 $\Delta$ poxB)  
• Figure 2: pMW218gdhA  
• Figure 3: pMW219rhtC

The length data are to be understood as approx. data. The abbreviations and designations used have the following  
15 meaning:

- cat: chloramphenicol resistance gene  
rep-ts: temperature-sensitive replication region of the plasmid pSC101  
poxB1: part of the 5' region of the poxB gene  
20 poxB2: part of the 3' region of the poxB gene  
kan: kanamycin resistance gene

gdhA: glutamate dehydrogenase gene

rhtC: gene imparting threonine resistance

The abbreviations for the restriction enzymes have the following meaning

- 5 • BamHI: restriction endonuclease from *Bacillus amyloliquefaciens*
- BglII: restriction endonuclease from *Bacillus globigii*
- ClaI: restriction endonuclease from *Caryophanon latum*
- 10 • Ecl136II: restriction endonuclease from *Enterobacter cloacae* RFL136 (= Ecl136)
- EcoRI: restriction endonuclease from *Escherichia coli*
- EcoRV: restriction endonuclease from *Escherichia coli*
- HindIII: restriction endonuclease from *Haemophilus influenzae*
- 15 • KpnI: restriction endonuclease from *Klebsiella pneumoniae*
- PstI: restriction endonuclease from *Providencia stuartii*
- PvuI: restriction endonuclease from *Proteus vulgaris*
- 20 • SacI: restriction endonuclease from *Streptomyces achromogenes*
- SalI: restriction endonuclease from *Streptomyces albus*
- 25 • SmaI: restriction endonuclease from *Serratia marcescens*

- XbaI: restriction endonuclease from *Xanthomonas badrii*
- XhoI: restriction endonuclease from *Xanthomonas holcicola*

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

Degussa-Hüls AG  
Kantstr. 2

33790 Halle

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
Identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: MG442ΔpoxB	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 13762
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by:  (X) a scientific description (X) a proposed taxonomic designation  (Mark with a cross where applicable).	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2000-10-02 (Date of the original deposit) <sup>1</sup> .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH  Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  <i>V. Weils</i>  Date: 2000-10-06

<sup>1</sup> Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE


## INTERNATIONAL FORM

Degussa-Hüls AG  
Kantstr. 2

33790 Halle

## VIABILITY STATEMENT

issued pursuant to Rule 10.2 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

I. DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM
Name: Degussa-Hüls AG Kantstr. 2 Address: 33790 Halle	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 13762  Date of the deposit or the transfer <sup>1</sup> : 2000-10-02
III. VIABILITY STATEMENT	
The viability of the microorganism identified under II above was tested on 2000-10-04 <sup>2</sup> . On that date, the said microorganism was  <input checked="" type="checkbox"/> viable  <input type="checkbox"/> no longer viable	
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED <sup>3</sup>	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH  Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):    Date: 2000-10-06

<sup>1</sup> Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).<sup>2</sup> In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.<sup>3</sup> Mark with a cross the applicable box.<sup>4</sup> Fill in if the information has been requested and if the results of the test were negative.

What is claimed is:

1. A process for the fermentative preparation of L-amino acids, in particular L-threonine, which comprises carrying out the following steps:
  - 5 a) fermentation of the microorganisms of the Enterobacteriaceae family which produce the desired L-amino acid and in which at least the poxB gene or nucleotide sequences which code for it are attenuated, in particular eliminated,
  - 10 b) concentration of the L-amino acid in the medium or in the cells of the bacteria and
  - c) isolation of the L-amino acid.
2. A process as claimed in claim 1, wherein L-threonine, L-valine or L-lysine is prepared.
- 15 3. A process as claimed in claim 1, which comprises employing microorganisms in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced.
4. A process as claimed in claim 1, which comprises  
20 employing microorganisms in which the metabolic pathways which reduce the formation of the desired L-amino acid are at least partly eliminated.
5. A process as claimed in claim 1, which comprises  
25 attenuating, in particular eliminating, expression of the polynucleotide(s) which code(s) for the poxB gene.
6. A process as claimed in claim 1, which comprises reducing the regulatory and/or catalytic properties of the polypeptide (enzyme protein) for which the polynucleotide poxB codes.

7. A process as claimed in claim 1, which comprises fermenting, for the preparation of L-amino acids, microorganisms of the Enterobacteriaceae family in which one or more genes chosen from the group consisting of:

- 7.1 the thrABC operon which codes for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase,
- 7.2 the pyc gene which codes for pyruvate carboxylase,
- 7.3 the pps gene which codes for phosphoenol pyruvate synthase,
- 7.4 the ppc gene which codes for phosphoenol pyruvate carboxylase,
- 7.5 the pntA and pntB genes which code for transhydrogenase,
- 7.6 the rhtB gene which imparts homoserine resistance,
- 7.7 the mqo gene which codes for malate:quinone oxidoreductase,
- 7.8 the rhtC gene which imparts threonine resistance,
- 7.9 the thrE gene which codes for threonine export and
- 7.10 the gdhA gene which codes for glutamate dehydrogenase

is or are enhanced, in particular over-expressed, at the same time.

8. A process as claimed in claim 1, which comprises fermenting, for the preparation of L-amino acids, microorganisms of the Enterobacteriaceae family in

which one or more genes chosen from the group consisting of:

- 8.1 the tdh gene which codes for threonine dehydrogenase,
- 5 8.2 the mdh gene which codes for malate dehydrogenase,
- 8.3 the gene product of the open reading frame (orf) yjfa,
- 8.4 the gene product of the open reading frame (orf) ytfP, and
- 10 8.5 the pckA gene which codes for the enzyme phosphoenol pyruvate carboxykinase,

is or are attenuated, in particular eliminated or reduced in expression, at the same time.

- 15 9. A process as claimed in claim 1 or 2, which comprises employing, for the preparation of L-threonine, the strain MG442ApoxB transformed with the plasmid pMW218gdhA, shown in figure 2.
- 20 10. A process as claimed in claim 1 or 2, which comprises employing, for the preparation of L-threonine, the strain MG442ApoxB transformed with the plasmid pMW219rhtC, shown in figure 3.
- 11. A process as claimed in claim 1 or 2, which comprises employing, for the preparation of L-lysine, the strain TOC21RApoxB.
- 25 12. A process as claimed in claim 1 or 2, which comprises employing, for the preparation of L-valine, the strain B-12288ApoxB.
- 13. A microorganism of the Enterobacteriaceae family which produces L-amino acids, in which the poxB gene or



nucleotides sequences which code for it are attenuated, in particular eliminated, and which have a resistance to  $\alpha$ -amino- $\beta$ -hydroxyvaleric acid and optionally a compensatable partial need for L-isoleucine.

- 5 14. The *Escherichia coli* K-12 strain MG442 $\Delta$ poxB deposited at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) under no. DSM 13762.
- 10 15. The plasmid pMAK705 $\Delta$ poxB, which contains parts of the 5' and of the 3' region of the poxB gene, corresponding to SEQ ID No. 3, shown in figure 1.
16. The plasmid pMW218gdhA shown in figure 2.
17. The plasmid pMW219rhtC shown in figure 3.
- 15 18. An isolated polynucleotide from microorganisms of the Enterobacteriaceae family, containing a polynucleotide sequence which codes for the 5' and 3' region of the poxB gene, shown in SEQ ID No. 4, in particular suitable as a constituent of plasmids for position-specific mutagenesis of the poxB gene.
- 20 19. A strain of the Enterobacteriaceae family which produces L-threonine and contains a mutation in the poxB gene, corresponding to SEQ ID No. 4.

Figure 1:




Figure 2:





Figure 3:



## SEQUENCE PROTOCOL

&lt;110&gt; Degussa AG

5 <120> Process for the fermentative preparation of  
L-amino acids using strains of the Enterobacteriaceae  
family.

10 <130> 000613 BT

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 4

15 <170> PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 1719

20 <212> DNA

&lt;213&gt; Escherichia coli

&lt;220&gt;

&lt;221&gt; CDS

25 <222> (1)..(1716)

&lt;223&gt; poxB

&lt;400&gt; 1

30 atg aaa caa acg gtt gca gct tat atc gcc aaa aca ctc gaa tcg gca 48  
Met Lys Gln Thr Val Ala Ala Tyr Ile Ala Lys Thr Leu Glu Ser Ala  
1 5 10 15

35 ggg gtg aaa cgc atc tgg gga gtc aca ggc gac tct ctg aac ggt ctt 96  
Gly Val Lys Arg Ile Trp Gly Val Thr Gly Asp Ser Leu Asn Gly Leu  
20 25 30

40 agt gac agt ctt aat cgc atg ggc acc atc gag tgg atg tcc acc cgc 144  
Ser Asp Ser Leu Asn Arg Met Gly Thr Ile Glu Trp Met Ser Thr Arg  
35 40 45

45 cac gaa gaa gtg gcg gcc ttt gcc gct ggc gct gaa gca caa ctt agc 192  
His Glu Glu Val Ala Ala Phe Ala Ala Gly Ala Glu Ala Gln Leu Ser  
50 55 60

50 gga gaa ctg gcg gtc tgc gcc gga tcg tgc ggc ccc ggc aac ctg cac 240  
Gly Glu Leu Ala Val Cys Ala Gly Ser Cys Gly Pro Gly Asn Leu His  
65 70 75 80

55 tta atc aac ggc ctg ttc gat tgc cac cgc aat cac gtt ccg gta ctg 288  
Leu Ile Asn Gly Leu Phe Asp Cys His Arg Asn His Val Pro Val Leu  
85 90 95

60 gcg att gcc gct cat att ccc tcc agc gaa att ggc agc ggc tat ttc 336  
Ala Ile Ala Ala His Ile Pro Ser Ser Glu Ile Gly Ser Gly Tyr Phe  
100 105 110

cag gaa acc cac cca caa gag cta ttc cgc gaa tgt agt cac tat tgc 384  
Gln Glu Thr His Pro Gln Glu Leu Phe Arg Glu Cys Ser His Tyr Cys  
115 120 125

		gag	ctg	gtt	tcc	agc	ccg	gag	cag	atc	cca	caa	gta	ctg	gcg	att	gcc	432
		Glu	Leu	Val	Ser	Ser	Pro	Glu	Gln	Ile	Pro	Gln	Val	Leu	Ala	Ile	Ala	
		130						135					140					
5		atg	cgc	aaa	gcg	gtg	ctt	aac	cgt	ggc	gtt	tcg	gtt	gtc	gtg	tta	cca	480
		Met	Arg	Lys	Ala	Val	Leu	Asn	Arg	Gly	Val	Ser	Val	Val	Val	Leu	Pro	
		145					150					155					160	
10		ggc	gac	gtg	gcg	tta	aaa	cct	gcg	cca	gaa	ggg	gca	acc	atg	cac	tgg	528
		Gly	Asp	Val	Ala	Leu	Lys	Pro	Ala	Pro	Glu	Gly	Ala	Thr	Met	His	Trp	
						165					170					175		
15		tat	cat	gcg	cca	caa	cca	gtc	gtg	acg	ccg	gaa	gaa	gaa	gag	tta	cgc	576
		Tyr	His	Ala	Pro	Gln	Pro	Val	Val	Thr	Pro	Glu	Glu	Glu	Glu	Leu	Arg	
					180					185						190		
20		aaa	ctg	gcg	caa	ctg	ctg	cgt	tat	tcc	agc	aat	atc	gcc	ctg	atg	tgt	624
		Lys	Leu	Ala	Gln	Leu	Leu	Arg	Tyr	Ser	Ser	Asn	Ile	Ala	Leu	Met	Cys	
				195				200						205				
25		ggc	agc	ggc	tgc	gcg	ggg	gcg	cat	aaa	gag	tta	gtt	gag	ttt	gcc	ggg	672
		Gly	Ser	Gly	Cys	Ala	Gly	Gly	His	Lys	Glu	Leu	Val	Glu	Phe	Ala	Gly	
			210					215					220					
30		aaa	att	aaa	gcg	cct	att	gtt	cat	gcc	ctg	cgc	ggt	aaa	gaa	cat	gtc	720
		Lys	Ile	Lys	Ala	Pro	Ile	Val	His	Ala	Leu	Arg	Gly	Lys	Glu	His	Val	
			225				230					235					240	
35		gaa	tac	gat	aat	ccg	tat	gat	gtt	gga	atg	acc	ggg	tta	atc	ggc	ttc	768
		Glu	Tyr	Asp	Asn	Pro	Tyr	Asp	Val	Gly	Met	Thr	Gly	Leu	Ile	Gly	Phe	
					245						250					255		
40		tcg	tca	ggt	ttc	cat	acc	atg	atg	aac	gcc	gac	acg	tta	gtg	cta	ctc	816
		Ser	Ser	Gly	Phe	His	Thr	Met	Met	Asn	Ala	Asp	Thr	Leu	Val	Leu	Leu	
					260					265					270			
45		ggc	acg	caa	ttt	ccc	tac	cgc	gcc	ttc	tac	ccg	acc	gat	gcc	aaa	atc	864
		Gly	Thr	Gln	Phe	Pro	Tyr	Arg	Ala	Phe	Tyr	Pro	Thr	Asp	Ala	Lys	Ile	
				275					280					285				
50		att	cag	att	gat	atc	aac	cca	gcc	agc	atc	ggc	gct	cac	agc	aag	gtg	912
		Ile	Gln	Ile	Asp	Ile	Asn	Pro	Ala	Ser	Ile	Gly	Ala	His	Ser	Lys	Val	
			290					295					300					
55		gat	atg	gca	ctg	gtc	ggc	gat	atc	aag	tcg	act	ctg	cgt	gca	ttg	ctt	960
		Asp	Met	Ala	Leu	Val	Gly	Asp	Ile	Lys	Ser	Thr	Leu	Arg	Ala	Leu	Leu	
			305				310					315					320	
60		cca	ttg	gtg	gaa	gaa	aaa	gcc	gat	cgc	aag	ttt	ctg	gat	aaa	gcg	ctg	1008
		Pro	Leu	Val	Glu	Glu	Lys	Ala	Asp	Arg	Lys	Phe	Leu	Asp	Lys	Ala	Leu	
						325					330					335		
65		gaa	gat	tac	cgc	gac	gcc	cgc	aaa	ggg	ctg	gac	gat	tta	gct	aaa	ccg	1056
		Glu	Asp	Tyr	Arg	Asp	Ala	Arg	Lys	Gly	Leu	Asp	Asp	Leu	Ala	Lys	Pro	
					340					345					350			
70		agc	gag	aaa	gcc	att	cac	ccg	caa	tat	ctg	gcg	cag	caa	att	agt	cat	1104
		Ser	Glu	Lys	Ala	Ile	His	Pro	Gln	Tyr	Leu	Ala	Gln	Gln	Ile	Ser	His	
				355						360					365			

	ttt gcc gcc gat gac gct att ttc acc tgt gac gtt ggt acg cca acg	1152
	Phe Ala Ala Asp Asp Ala Ile Phe Thr Cys Asp Val Gly Thr Pro Thr	
	370 375 380	
5	gtg tgg gcg gca cgt tat cta aaa atg aac ggc aag cgt cgc ctg tta	1200
	Val Trp Ala Ala Arg Tyr Leu Lys Met Asn Gly Lys Arg Arg Leu Leu	
	385 390 395 400	
10	ggt tgc ttt aac cac ggt tgc atg gct aac gcc atg ccg cag gcg ctg	1248
	Gly Ser Phe Asn His Gly Ser Met Ala Asn Ala Met Pro Gln Ala Leu	
	405 410 415	
15	ggt gcg cag gcg aca gag cca gaa cgt cag gtg gtc gcc atg tgc ggc	1296
	Gly Ala Gln Thr Glu Pro Glu Arg Gln Val Val Ala Met Cys Gly	
	420 425 430	
20	gat ggc ggt ttt agc atg ttg atg ggc gat ttc ctc tca gta gtg cag	1344
	Asp Gly Gly Phe Ser Met Leu Met Gly Asp Phe Leu Ser Val Val Gln	
	435 440 445	
25	atg aaa ctg cca gtg aaa att gtc gtc ttt aac aac agc gtg ctg ggc	1392
	Met Lys Leu Pro Val Lys Ile Val Val Phe Asn Asn Ser Val Leu Gly	
	450 455 460	
30	ttt gtg gcg atg gag atg aaa gct ggt ggc tat ttg act gac ggc acc	1440
	Phe Val Ala Met Glu Met Lys Ala Gly Gly Tyr Leu Thr Asp Gly Thr	
	465 470 475 480	
35	gaa cta cac gac aca aac ttt gcc cgc att gcc gaa gcg tgc ggc att	1488
	Glu Leu His Asp Thr Asn Phe Ala Arg Ile Ala Glu Ala Cys Gly Ile	
	485 490 495	
40	acg ggt atc cgt gta gaa aaa gcg tct gaa gtt gat gaa gcc ctg caa	1536
	Thr Gly Ile Arg Val Glu Lys Ala Ser Glu Val Asp Glu Ala Leu Gln	
	500 505 510	
45	gcg gcc ttc tcc atc gac ggt ccg gtg ttg gtg gat gtg gtg gtc gcc	1584
	Arg Ala Phe Ser Ile Asp Gly Pro Val Leu Val Asp Val Val Val Ala	
	515 520 525	
50	aaa gaa gag tta gcc att cca ccg cag atc aaa ctc gaa cag gcc aaa	1632
	Lys Glu Glu Leu Ala Ile Pro Pro Gln Ile Lys Leu Glu Gln Ala Lys	
	530 535 540	
55	ggt ttc agc ctg tat atg ctg cgc gca atc atc agc gga cgc ggt gat	1680
	Gly Phe Ser Leu Tyr Met Leu Arg Ala Ile Ile Ser Gly Arg Gly Asp	
	545 550 555 560	
60	gaa gtg atc gaa ctg gcg aaa aca aac tgg cta agg taa	1719
	Glu Val Ile Glu Leu Ala Lys Thr Asn Trp Leu Arg	
	565 570	
	<210> 2	
	<211> 572	
	<212> PRT	
	<213> Escherichia coli	
	<400> 2	
	Met Lys Gln Thr Val Ala Ala Tyr Ile Ala Lys Thr Leu Glu Ser Ala	
	1 5 10 15	
	Gly Val Lys Arg Ile Trp Gly Val Thr Gly Asp Ser Leu Asn Gly Leu	

	20	25	30
5	Ser Asp Ser 35	Leu Asn Arg Met Gly 40	Thr Ile Glu Trp Met 45
	His Glu Glu 50	Val Ala Ala Phe 55	Ala Gly Ala Glu 60
10	Gly Glu Leu 65	Ala Val Cys 70	Gly Ser Cys Gly 75
	Leu Ile Asn Gly 85	Leu Phe Asp Cys 90	His Arg Asn His 95
15	Ala Ile Ala 100	Ala His Ile Pro 105	Ser Glu Ile Gly 110
	Gln Glu Thr 115	His Pro Gln Glu 120	Phe Arg Glu Cys 125
20	Glu Leu Val 130	Ser Ser Pro Glu 135	Gln Ile Pro Gln 140
	Met Arg Lys 145	Ala Val Leu Asn 150	Arg Gly Val Ser 155
25	Gly Asp Val 165	Ala Leu Lys Pro 170	Ala Thr Met His 175
30	Tyr His Ala 180	Pro Gln Pro Val 185	Thr Pro Glu Glu 190
	Lys Leu Ala 195	Gln Leu Leu Arg 200	Tyr Ser Ser Asn 205
35	Gly Ser Gly 210	Cys Ala Gly 215	His Lys Glu Leu 220
	Lys Ile Lys 225	Ala Pro Ile Val 230	His Ala Leu Arg 235
40	Glu Tyr Asp 245	Asn Pro Tyr Asp 250	Val Gly Met Thr 255
	Ser Ser Gly 260	Phe His Thr Met 265	Asn Ala Asp Thr 270
45	Gly Thr Gln 275	Phe Pro Tyr Arg 280	Ala Phe Tyr Pro 285
50	Ile Gln Ile 290	Asp Ile Asn Pro 295	Ala Ser Ile Gly 300
	Asp Met Ala 305	Leu Val Gly 310	Asp Ile Lys Ser 315
55	Pro Leu Val 325	Glu Glu Lys Ala 330	Asp Arg Lys Phe 335
	Glu Asp Tyr 340	Arg Asp Ala Arg 345	Lys Gly Leu Asp 350
60	Ser Glu Lys Ala 355	Ile His Pro Gln 360	Tyr Leu Ala Gln 365
			Ile Ser His



355 360 365  
 Phe Ala Ala Asp Asp Ala Ile Phe Thr Cys Asp Val Gly Thr Pro Thr  
 370 375 380  
 5 Val Trp Ala Ala Arg Tyr Leu Lys Met Asn Gly Lys Arg Arg Leu Leu  
 385 390 395 400  
 10 Gly Ser Phe Asn His Gly Ser Met Ala Asn Ala Met Pro Gln Ala Leu  
 405 410 415  
 Gly Ala Gln Ala Thr Glu Pro Glu Arg Gln Val Val Ala Met Cys Gly  
 420 425 430  
 15 Asp Gly Gly Phe Ser Met Leu Met Gly Asp Phe Leu Ser Val Val Gln  
 435 440 445  
 Met Lys Leu Pro Val Lys Ile Val Val Phe Asn Asn Ser Val Leu Gly  
 450 455 460  
 20 Phe Val Ala Met Glu Met Lys Ala Gly Gly Tyr Leu Thr Asp Gly Thr  
 465 470 475 480  
 25 Glu Leu His Asp Thr Asn Phe Ala Arg Ile Ala Glu Ala Cys Gly Ile  
 485 490 495  
 Thr Gly Ile Arg Val Glu Lys Ala Ser Glu Val Asp Glu Ala Leu Gln  
 500 505 510  
 30 Arg Ala Phe Ser Ile Asp Gly Pro Val Leu Val Asp Val Val Val Ala  
 515 520 525  
 Lys Glu Glu Leu Ala Ile Pro Pro Gln Ile Lys Leu Glu Gln Ala Lys  
 530 535 540  
 35 Gly Phe Ser Leu Tyr Met Leu Arg Ala Ile Ile Ser Gly Arg Gly Asp  
 545 550 555 560  
 40 Glu Val Ile Glu Leu Ala Lys Thr Asn Trp Leu Arg  
 565 570

45 <210> 3  
 <211> 1454  
 <212> DNA  
 <213> Escherichia coli

50 <220>  
 <221> misc\_feature  
 <222> (1)..(1454)  
 <223> Mutagenic DNA

55 <220>  
 <221> misc\_feature  
 <222> (1)..(56)  
 <223> Technical DNA/residues of the polylinker sequence

60 <220>  
 <221> misc\_feature  
 <222> (57)..(577)  
 <223> Part of the 5' region (poxB1) of the poxB gene

<220>  
<221> misc feature  
<222> (578)..(646)  
<223> Technical DNA/residues of the polylinker sequence

5  
<220>  
<221> misc feature  
<222> (647)..(1398)  
<223> Part of the 3' region (poxB2) of the poxB gene

10  
<220>  
<221> misc feature  
<222> (1399)..(1454)  
<223> Technical DNA/residues of the polylinker sequence

15  
<400> 3  
ctagatgcat gctcgcgagcgg ccgccagtgat gatggatatac tgcagaattc gccctttctga 60  
acgggtcttag tgacagtcctt aatcgcagtg gacccatcga gtggatgtcc acccgccacg 120  
aagaagtggc ggcctttgccc gctggcgctg aagcacaact tagcggagaa ctggcggtct 180  
20 gcgcgggac gtgcggcccc ggcaacctgc acttaataca cggcctgttc gattgccacc 240  
gcaatcacgt tccggtactg gcgattgccg tctcatattcc ctccagcgaa attggcagcg 300  
gctatttcca ggaaacccac ccacaagagc tattccgcga atgtagtcac tattgcgagc 360  
tggtttccag cccggagcag atcccacaag tactggcgat tgccatgcgc aaagcgggtgc 420  
ttaaccgtgg cgtttcggtt gtcgtgttac caggcgacgt ggcgttaaaa cctgcgccag 480  
25 aaggggcaac catgcactgg tatcatgcgc cacaaccagt cgtgacgccg gaagaagaag 540  
agttacgcaa actggcgcaa ctgctgcgtt attccaggcc taagggcgaa ttccagcaca 600  
ctggcgggcg ttactagtgg atccgagatc tgcagaattc gcccttctgc gtgcattgct 660  
tccattgggtg gaagaaaaag ccgatcgcaa gtttctggat aaagcgctgg aagattaccg 720  
cgacgccccg aaagggctgg acgatttagc taaaccgagc gagaaagcca ttcaccgcga 780  
30 atatctggcg cagcaaatga gtcattttgc cgccgatgac gctattttca cctgtgacgt 840  
tggtacgcca acggtgtggg cggcacgtta tctaaaaatg aacgggaagc gtcgcctggt 900  
aggttcgttt aaccacggtt cgatggctaa cgccatgccg caggcgctgg gtgcgcaggc 960  
gacagagcca gaacgtcagg tggtcgccat gtgcggcgat ggcggtttta gcatgttgat 1020  
ggcgatattc ctctcagtag tgcagatgaa actgccagtg aaaattgtcg tctttaacaa 1080  
35 cagcgtgctg ggctttgtgg cgatggagat gaaagctggt ggctatttga ctgacggcac 1140  
cgaactacac gacacaaaact ttgcccgcgt tgccgaagcg tgcggcatta cgggtatccg 1200  
ttagaaaaaa gcgtctgaag ttgatgaagc cctgcaacgc gccttctcca tcgacgggtcc 1260  
ggtgttggtg gatgtggtgg tcgccaaaaga agagtttagc attccaccgc agatcaaact 1320  
cgaacaggcc aaaggtttca gcctgtatat gctgcgcgca atcatcagcg gacgcgggtga 1380  
40 tgaagtgtac gaactggcaa gggcgaattc cagcacactg gcggccgtta ctagtggatc 1440  
cgagctcggt acca 1454

45  
<210> 4  
<211> 1448  
<212> DNA  
<213> Escherichia coli

50  
<220>  
<221> misc feature  
<222> (1)..(3)  
<223> Start codon of the delta poxB allele

55  
<220>  
<221> misc feature  
<222> (1)..(605)  
<223> 5' region of the delta poxB allele

60  
<220>  
<221> misc feature  
<222> (606)..(674)  
<223> Technical DNA/residues of the polylinker sequence  
<220>

<221> misc feature  
<222> (675)..(1445)  
<223> 3' region of the delta poxB allele

5 <220>  
<221> misc feature  
<222> (1446)..(1448)  
<223> Stop codon of the delta poxB allele

10 <400> 4  
atgaaacaaa cggttgcagc ttatatcgcc aaaacactcg aatcggcagg ggtgaaacgc 60  
atctggggag tcacaggcga ctctctgaac ggtcttagtg acagtcctta tgcgatgggc 120  
accatcgagt ggatgtccac ccgccacgaa gaagtggcgg cctttgccgc tggcgctgaa 180  
gcacaactta gcggagaact ggcggtctgc aatcacgttc cggactggc gattgccgct 240  
15 ttaatcaacg gcctgttcga ttgccaccgc aatcacgttc cggactggc gattgccgct 300  
catattccct ccagcgaaat tggcagcggc tatttccagg aaacccaccc acaagagcta 360  
ttccgcgaat gtagtcacta ttgcgagctg gtttccagcc cggagcagat cccacaagta 420  
ctggcgattg ccatgcgcaa agcgggtgctt aaccgtggcg ttctcggttg cgtgttacca 480  
ggcgacgtgg cggtaaaacc tgcgccagaa ggggcaacca tgcactggta tcatgcgcca 540  
20 caaccagtcg tgacgccgga agaagaagag ttacgcaaac tggcgcaact gctgcgttat 600  
tccaggccta agggcgaaat ccagcacact ggcggccggt actagtggat ccgagatctg 660  
cagaattcgc ccttctgcgt gcattgcttc cattgggtgga agaaaaagcc gatcgcaagt 720  
ttctggataa agcgttgaa gattaccgcg acgcccgcaa agggctggac gatttagcta 780  
aaccgagcga gaaagccatt caccgcgaat atctggcgca gcaaattagt cattttgccg 840  
25 ccgatgacgc tattttcacc tgtgacgttg gtacgccaac ggtgtggcg gcacgttatc 900  
taaaaatgaa cggcaagcgt cgctgttag gttcgtttta ccacggttcg atggctaacg 960  
ccatgccgca ggcgtgggt gcgcaggcga cagagccaga acgtcagggt gtcgccatgt 1020  
gcggcgatgg cggttttagc atgttgatgg gcgtgctggg ctttgtggcg atggagatga 1140  
30 tgccagtga aattgtcgtc tttaacaaca gcgtgctggg ctttgtggcg atggagatga 1140  
aagctggtgg ctatttgact gacggcaccg aactacacga cacaaacttt gcccgcattg 1200  
ccgaagcgtg cggcattacg ggtatccgtg tagaaaaagc gtctgaagtt gatgaagccc 1260  
tgcaacgcgc cttctccatc gacggtcagg tggtgggtga tgtggtggc gccaaagaag 1320  
agttagccat tccaccgcag atcaaaactc aacaggccaa aggtttcagc ctgtatatgc 1380  
35 tgcgcgcaat catcagcgga cgcggtgatg aagtgatcga actggcgaaa acaaactggc 1440  
taaggtaa 1448

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 May 2002 (10.05.2002)

PCT

(10) International Publication Number  
WO 02/036797 A3

(51) International Patent Classification<sup>7</sup>: C12N 15/53, 15/52, 15/70, C12P 13/08, C12N 9/02, 1/21

(21) International Application Number: PCT/EP01/11228

(22) International Filing Date:  
28 September 2001 (28.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
100 54 748.6 4 November 2000 (04.11.2000) DE  
60/248,210 15 November 2000 (15.11.2000) US  
101 12 107.5 14 March 2001 (14.03.2001) DE  
60/283,612 16 April 2001 (16.04.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report

(71) Applicant: DEGUSSA AG [DE/DE]; Bennigseplatz 1, 40474 Düsseldorf (DE).

(88) Date of publication of the international search report:  
14 November 2002

(72) Inventors: RIEPING, Mechthild; Mönkebergstrasse 1, 33619 Bielefeld (DE). THIERBACH, Georg; Gunststrasse 21, 33613 Bielefeld (DE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/036797 A3

(54) Title: PROCESS FOR THE FERMENTATIVE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEAE FAMILY

(57) Abstract: The invention relates to a process for the fermentative preparation of L-amino acids, in particular L-threonine, in which the following steps are carried out: a) fermentation of the microorganisms of the Enterobacteriaceae family which produce

## INTERNATIONAL SEARCH REPORT

Int ional Application No

PCT/EP 01/11228

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12N15/52 C12N15/70 C12P13/08 C12N9/02  
C12N1/21

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, SEQUENCE SEARCH, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE; PHILADELPHIA, PA, US; 1989 GRABAU C ET AL: "LIPID BINDING BY ESCHERICHIA-COLI PYRUVATE OXIDASE IS DISRUPTED BY SMALL ALTERATIONS OF THE CARBOXYL-TERMINAL REGION" Database accession no. PREV198988088849 XP002208064 abstract & JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 21, 1989, pages 12510-12519, ISSN: 0021-9258 — -/-	1-19

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Z\* document member of the same patent family

Date of the actual completion of the international search

30 July 2002

Date of mailing of the international search report

14/08/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 apo nl,  
Fax (+31-70) 340-3016

Authorized officer

Douschan, K

## INTERNATIONAL SEARCH REPORT

 Int. Application No  
 PCT/EP 01/11228

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHANG Y-Y ET AL: "MOLECULAR CLONING, DNA SEQUENCING, AND ENZYMATIC ANALYSES OF TWO ESCHERICHIA COLI PYRUVATE OXIDASE MUTANTS DEFECTIVE IN ACTIVATION BY LIPIDS" JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 167, no. 1, July 1986 (1986-07), pages 312-318, XP000987283 ISSN: 0021-9193 the whole document	1-19
A	GRABAU C ET AL: "MOLECULAR CLONING OF THE GENE (POXB) ENCODING THE PYRUVATE OXIDASE OF ESCHERICHIA COLI, A LIPID-ACTIVATED ENZYME" JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 160, no. 3, December 1984 (1984-12), pages 1088-1092, XP000987282 ISSN: 0021-9193 the whole document	1-19
A	US 4 278 765 A (DEBBOV V. G. ET AL.) 14 July 1981 (1981-07-14) cited in the application the whole document	1-19
A	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1987 VAN DYK T K ET AL: "PLEIOTROPIC EFFECTS OF POX-A REGULATORY MUTATIONS OF ESCHERICHIA-COLI AND SALMONELLA-TYPHIMURIUM MUTATIONS CONFERRING SULFOMETURON METHYL AND ALPHA KETO BUTYRATE HYPERSENSITIVITY" Database accession no. PREV198784118407 XP002208065 abstract & JOURNAL OF BACTERIOLOGY, vol. 169, no. 10, 1987, pages 4540-4546, ISSN: 0021-9193	13,19
A,P	WO 01 71012 A (DEGUSSA AG) 27 September 2001 (2001-09-27) claim 7	1-19
A,P	EP 1 096 013 A (DEGUSSA G) 2 May 2001 (2001-05-02) claims 1-16	1-19

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/11228

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4278765	A	14-07-1981	SU 875663 A1 HU 190999 B	15-09-1982 28-12-1986
WO 0171012	A	27-09-2001	AU 6431600 A BR 0010817 A CN 1350586 T WO 0171012 A1 EP 1179076 A1	03-10-2001 05-03-2002 22-05-2002 27-09-2001 13-02-2002
EP 1096013	A	02-05-2001	DE 19951975 A1 AU 6807500 A BR 0005091 A CN 1304997 A EP 1096013 A2 JP 2001161386 A SK 15732000 A3	03-05-2001 03-05-2001 19-06-2001 25-07-2001 02-05-2001 19-06-2001 06-11-2001

Form PCT/ISA/210 (patent family annex) (July 1992)